A pain study update provided a lift to a Canadian biopharma stock Tuesday. Here’s some small stocks making big moves on Tuesday, April 9, 2019 (as of 4 pm EST):
Tetra Bio-Pharma Inc. (TSXV:TBP), a biopharma stock, gained 11% to $0.71 on Tuesday after announcing that it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health-Related Quality of Life.
As well, shares of Erin Ventures Inc. (TSXV:EV) slid 21% to $0.095 as the junior explorer said InvestCo has informed the Company that it is unable to exercise the funding option for the development of Erin’s Piskanja boron project as a result of InvestCo’s imminent internal corporate restructuring.
Liberty Defense Holdings, Ltd. (TSXV:SCAN) stock, meanwhile, commenced trading on the TSX Venture Exchange on Tuesday. Liberty Defense Holdings is a security solutions and technology company for concealed weapons detection.
Finally, Khiron Life Sciences Corp. (TSXV:KHRN) shares eased 1% to $3.54 after the Latin America-focused medical cannabis company announced that it has agreed to acquire NettaGrowth International Inc., a Uruguayan company that has obtained the first license to produce and export medical cannabis with THC for commercialization in Uruguay, in consideration for 8,498,821 Khiron common shares at a deemed price of $1.61 per common share.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Tetra Bio-Pharma Inc. (TSXV:TBP), a biopharma stock, gained 11% to $0.71 on Tuesday after announcing that it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health-Related Quality of Life.
